Literature DB >> 16788098

Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes.

Alan L Parker1, Simon N Waddington, Campbell G Nicol, Dmitry M Shayakhmetov, Suzanne M Buckley, Laura Denby, Geoffrey Kemball-Cook, Shaoheng Ni, Andre Lieber, John H McVey, Stuart A Nicklin, Andrew H Baker.   

Abstract

Upon local delivery, adenovirus (Ad) serotype 5 viruses use the coxsackie and Ad receptor (CAR) for cell binding and alpha(v) integrins for internalization. When administered systemically, however, their role in liver tropism is limited because CAR-permissive and mutated viruses show similar biodistribution, a finding recently attributed to blood coagulation factor (F) IX or complement protein C4BP binding to the adenovirus fiber and "bridging" to either low-density lipoprotein receptor-related protein or heparan sulfate proteoglycans. Here, we show that hepatocyte transduction in vitro can be enhanced by the vitamin K-dependent factors FX, protein C, and FVII in addition to FIX but not by prothrombin (FII), FXI, and FXII. This phenomenon was not dependent on proteolytic activation or cell signaling activity and for FX was mediated by direct virus-factor binding. Human FX substantially enhanced hepatocyte transduction by CAR-permissive and mutated viruses in an ex vivo liver perfusion model. In vivo, global down-regulation of vitamin K-dependent zymogens by warfarin significantly diminished liver uptake of CAR-deleted Ads; however, this phenomenon was fully rescued by acute infusion of human FX. Our results indicate a common and pivotal role for distinct vitamin K-dependent coagulation factors in mediating hepatocyte transduction by adenoviruses in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16788098     DOI: 10.1182/blood-2006-04-008532

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  149 in total

1.  Gene therapy to the kidney using viral vectors.

Authors:  Talha Akbulut; Frank Park
Journal:  Paidiatrike       Date:  2008

2.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Authors:  Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon N Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; Andre Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

3.  Construction of metabolically biotinylated adenovirus with deleted fiber knob as targeting vector.

Authors:  Yanzheng Liu; Philippe Valadon; Jan E Schnitzer
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

Review 4.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

Review 5.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

6.  Targeting adenoviruses with factor x-single-chain antibody fusion proteins.

Authors:  Christopher Y Chen; Shannon M May; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

7.  Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver.

Authors:  Daniel Stone; Ying Liu; Dmitry Shayakhmetov; Zong-Yi Li; Shaoheng Ni; André Lieber
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

8.  Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1.

Authors:  Sharmila Raman; Tien-Huei Hsu; Shanna L Ashley; Katherine R Spindler
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

9.  Circulating antibodies and macrophages as modulators of adenovirus pharmacology.

Authors:  Reeti Khare; Matthew L Hillestad; Zhili Xu; Andrew P Byrnes; Michael A Barry
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

10.  Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.

Authors:  Sergey A Kaliberov; Lyudmila N Kaliberova; Zhi Hong Lu; Meredith A Preuss; Justin A Barnes; Cecil R Stockard; William E Grizzle; Jeffrey M Arbeit; David T Curiel
Journal:  Virology       Date:  2013-10-15       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.